Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 6, 2008, Pages 664-671

  Pérez Simón, Jose A ^a   Martino, Rodrigo ^b   Caballero, Dolores ^a   Valcarcel, David ^b   Rebollo, Noemi ^a   de la Cámara, Rafael ^c   Pérez de Oteiza, Javier ^d   Heras, Inmaculada ^e   Calvo, Maria V ^a   Sierra, Jordi ^b   San Miguel, Jesús F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Allogeneic transplantation; Graft versus host disease; Mycophenolate mofetil; Reduced intensity conditioning; Unrelated donor

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REMISSION; REPEATED DRUG DOSE; UNRELATED DONOR; VOMITING;

EID: 43449103922     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.03.007     Document Type: Article

References (44)

1. E. Thomas R. Storb R. Clift Bone marrow transplantation N Eng J Med 292 1975 832 843
2. M. Lima R. Champlin Unrelated donor hematopoietic transplantation Rev Clin Exp Hematol 5 2001 100 134
3. C. Hurley L.A. Lowe B. Logan National Marrow Donor Program HLA matching guidelines for unrelated marrow transplants Biol Blood Marrow Transplant 9 2003 610 615
4. G. Dini R. Cancedda F. Locatelli Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Transplant Group (GITMO) Hematologica 86 2001 15 20
5. H. Castro-Malaspina R. Harris J. Gajewski Unrelated donor marrow transplantation for myelodisplastic síndromes: outcome análisis in 510 transplants facilitated by the National Marrow Donor Program Blood 99 2002 1943 1951
6. N. Flomemberg L.A. Baxter-Lowe D.L. Confer Impact of class I and LL high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome Blood 104 2004 1923 1930
7. D. Winston R. Maziarz P. Chandrasekar Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients Ann Intern Med 138 2003 705 713
8. M. Slavin B. Osborne R. Adams Efficacy and safety of fluconazol prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double blind study J Infect Dis 171 1995 1545 1554
9. C.Q. Xun J.S. Thompson S. Jeyapalan Effect of total body irradiation, busulphan-cyclophsophamide or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft versus host disease in H-2 incompatible transplanted SCID mice Blood 83 1994 2360 2367
10. V. Ratanatharathorn R. Nash D. Przepiorka Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for graft versus host disease prophylaxis after HLA identical sibling bone marrow transplantation Blood 92 1998 2303 2314
11. D. Weisdorf C. Anasetti J. Antin Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation Blood 15 2002 1971 1977
12. I. Yakoub-Agha F. Mensil M. Kuentz Allogeneic marrow stem cell transplantation from human leukocyte antigen identical sibling versus human leukocyte antigen matched unrelated donor (10/10) in patients with standard risk hematopoietic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy J Clin Oncol 24 2006 5695 5702
13. E. Carreras J.F. Tomás G. Sanz Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience Hematologica 85 2000 530 538
14. P. McGlave X. Shu W. Wen Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program Blood 95 2000 2219 2225
15. J. Cornelissen M. Carston C. Kollman Unrelated marrow transplantation for adult patients with poor risk acute lymphoblastic leukemia: strong graft versus leukemmia effect and risk factors determining ourcome Blood 97 2001 1572 1577
16. J.P. Radich T. Gooley J.E. Sanders Second allogeneic transplantation after failure of first autologous transplantation Biol Blood Marrow Transplant 6 2000 272 279
17. T. Tsai S. Goodman R. Saez Allogeneic bone marrow transplantation in patients who relapse after an autologous transplantation Bone Marrow Transplant 20 1997 859 863
18. J.A. Pérez-Simón P. Kottaridis R. Martino Non-myeloablative transplants with or without CAMPATH-1H: comparison between two prospective studies in patients with lymphoproliferative disorders Blood 100 2002 3121 3127
19. N. Kröger B. Shaw S. Iacobelli Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma Br J Hematol 129 2005 631 643
20. S. Slavin A. Nagler E. Naparstek Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with letal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756 763
21. S. Giralt E. Estey M. Albitar Engraftment of allogeneic hematopoietic progenitor cells wirrh purine analog-containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy Blood 89 1997 4531 4536
22. R. Wong S. Giralt T. Martín Reduced intensity conditioning for unrelated donor hematopoietic transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 2003 3052 3059
23. N. Kröger H.G. Sayer R. Schwerdtfeger Unrelated stem cell transplantation in multiple myeloma after a reduced intensity conditioning with pretransplantation antithymmocyte globulin is highly effective with low transplantation related mortality Blood 100 2002 3919 3924
24. Z. Lim A. Ho W. Ingram Outcomes of alemtuzumab based reduced intensity conditioing stem cell transplantation using unrelated donors for myelodisplastic syndromes Br J Hematol 135 2006 201 209
25. J. Delgado K. Thomson N. Russell Results of alemtuzumab based reduced intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study Blood 107 2006 1724 1730
26. E. Morris K. Thomson C. Craddock Outcomes after alemtuzumab containing reduced intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma Blood 104 2004 3865 3871
27. B. Bolwell R. Sobecks B. Pohlman A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation Bone Marrow Transplant 34 2004 621 625
28. D. Przepiorka D. Weisdorf P. Martin 1994 Consensus conference on acute GVHD grading Bone Marrow Transplant 15 1995 825 828
29. K.M. Sullivan H.M. Shulman R. Storb Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression Blood 57 1981 267 276
30. R. Rodriguez P. Parker A. Nademanee Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies Bone Marrow Transplant 33 2004 1123 1129
31. M. Maris D. Niederwieser B. Sandmaier HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2003 2021 2030
32. J.A. Pérez-Simón M. Díez-Campelo R. Martino Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft versus host disease after allogeneic transplantation Br J Hematol 130 2005 394 403
33. M. Sorror M. Maris B. Storer Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic stem cell tramsplantation after non-myeloablative and myeloablative conditioning: influence of pretransplantation comorbidities Blood 104 2004 961 968
34. C. Kahl B.E. Storer B.M. Sandmaier M. Mielkarek Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood 110 2007 2744 2748
35. M. de Lima A. Anagnostopoulos M. Munsell Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865 872
36. D. Claxon C. Ehmann W. Rybka Control of advanced and refractory acute myelogenous leukemia with sirolimus based non-myeloablative allogeneic stem cell transplantation Br J Hematol 130 2005 256 264
37. D. Caballero J.A. García-Marco R. Martino Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-) Clin Cancer Res 11 2005 7757 7763
38. D. Valcárcel R. Martino D. Caballero Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival J Clin Oncol 26 2008 577 584
39. I. Yakoub-Agha F. Mesnil M. Kuentz Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy J Clin Oncol 24 2006 5695 5702
40. L.T. Weber M. Shipkova V.W. Armstrong The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy J Am Soc Nephrol 13 2002 759 768
41. L. Giaccone J.S. McCune M.B. Maris Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation Blood 106 2005 4381 4388
42. J. Jacobson J. Rogosheske J.N. Barker Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation Clin Pharmacol Ther 78 2005 486 500
43. V.C. Cox H.H. Ensom Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 25 2003 137 157
44. R.M. Van Hest R.A. Mathot A.G. Vulto Within-patient variability of mycophenolic acid exposure. Therapeutic drug monitoring from a clinical point of view Ther Drug Monit 28 2006 31 34